Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy

Rivera-Caravaca, Jose Miguel ORCID: 0000-0003-0492-6241, Esteve-Pastor, Maria Asuncion, Camelo-Castillo, Anny, Ramirez-Macias, Inmaculada, Lip, Gregory YH ORCID: 0000-0002-7566-1626, Roldan, Vanessa and Marin, Francisco (2020) Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy. Expert Opinion on Pharmacotherapy, 21 (15). pp. 1867-1881.

Text Manuscript - blinded - track changes[2].docx - Author Accepted Manuscript Download (455kB)

Abstract

Introduction Oral anticoagulants (OAC) reduce stroke/systemic embolism and mortality risks in atrial fibrillation (AF). However, there is an inherent bleeding risk with OAC, where intracranial hemorrhage (ICH) is the most feared, disabling, and lethal complication of this therapy. Therefore, the optimal management of OAC-associated ICH is not well defined despite multiple suggested strategies. Areas covered In this review, the authors describe the severity and risk factors for OAC-associated ICH and the associated implications for using DOACs in AF patients. We also provide an overview of the management of OAC-associated ICH and treatment reversal strategies, including specific and nonspecific reversal agents as well as a comprehensive summary of the evidence about the resumption of DOAC and the optimal timing.

Item Type:	Article
Uncontrolled Keywords:	Atrial fibrillation, oral anticoagulants, vitamin K antagonists, direct oral anticoagulants, intracranial hemorrhage, intracranial bleeding
Depositing User:	Symplectic Admin
Date Deposited:	14 Sep 2020 07:27
Last Modified:	18 Jan 2023 23:33
DOI:	10.1080/14656566.2020.1789099
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3101114